Anaphylactic shock or anaphylaxis is a severe and sometimes life-threatening immune system reaction to an antigen that a person has been previously exposed to. The reaction may include itchy skin, edema, collapsed blood vessels, fainting, difficulty in breathing, and death.
An Australian-first national analysis of 13 years' data on bites and stings from venomous creatures reveals Australia's towns and cities are a hot-spot for encounters.
An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.
The immune system orchestrates large and small scale attacks on innumerous targets: viruses, bacteria, cancer, but it also misfires causing allergy or autoimmune reactions.
Researchers in France have identified a molecular motor that controls the release of inflammatory factors that cause severe and fatal allergic reactions.
Most people have never heard of mastocytosis. It's a rare, sometimes deadly, immune disorder. Now new research may help those with advanced mastocytosis and possibly many more people, too.
Seaweed has long been a staple food in many Asian countries and has recently caught on as a snack food in America as a healthful alternative to chips. The edible algae that fall in the category of seaweed are low-calorie and packed with nutrients
Bring the drugs, hold the suds. That summarizes a promising new drug-making technique designed to reduce serious allergic reactions and other side effects from anti-cancer medicine, testosterone and other drugs that are administered with a needle.
Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.
New research from Karolinska Institutet in Sweden shows that hypersexual disorder - known popularly as sex addiction - can be linked to hyperactive stress systems. In a stress regulation test using the cortisone drug dexamethasone, men with hypersexual disorder showed higher levels of stress hormones than controls, a finding that the researchers hope will contribute to improved therapy for this patient group.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).
Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.
Parents of kids with severe allergies know how scary a severe allergic reaction (anaphylaxis) is. New research offers clues as to why some kids can have a second, related reaction hours later - and what to do about it.
Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.
Pfizer Canada Inc., the distributor of EpiPen, and the Montreal Bell Centre are pleased to announce that EpiPen (epinephrine) emergency kits are now available at the Bell Centre, home of the Montreal Canadiens hockey team. The new partnership strives to offer a safeguarded environment for visitors at risk of serious allergic reactions during hockey games, concerts and other entertainment events.
Current peanut allergy tests are not very reliable when it comes to diagnosing the severity of an individual's allergic reaction, which can range from hives to life-threatening anaphylactic shock.
Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
A popular new ingredient in gluten-free products could be causing an allergic reaction, according to a Kansas State University food safety specialist.
When summer rolls around, nothing beats soaking up the rays, hiking in a forest or playing Frisbee with the family … until a mosquito, bee or poisonous plant ruins the fun.
BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).